bendamustine hydrochloride has been researched along with Waldenstrom Macroglobulinemia in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 21 (58.33) | 24.3611 |
| 2020's | 15 (41.67) | 2.80 |
| Authors | Studies |
|---|---|
| Leslie, LA | 1 |
| Auer, R; D'Sa, S; El-Sharkawi, D; Kothari, J; Krishna, R; Kyriakou, C; McCarthy, H; Miles, O; Owen, R; Pratt, G | 1 |
| Colomo, L; Diez-Feijóo, R; Fernández-Rodríguez, C; Ferrer, A; Flores, S; Raya, C; Rodríguez-Sevilla, JJ; Salar, A | 1 |
| Branagan, AR; Castillo, JJ; Sarosiek, S; Sermer, D; Treon, SP | 1 |
| Kawano, K; Ohtsuka, E; Okuhiro, K; Saburi, M; Saburi, Y; Sakata, M; Uesugi, S; Urabe, S; Wada, J | 1 |
| Chen, CI; Doucette, S; Forward, N; Kaedbey, R; Sehn, LH; Shafey, M | 1 |
| Gertz, MA | 3 |
| Abeykoon, JP; Advani, R; Arulogun, SO; Branagan, AR; Buske, C; Cao, X; Castillo, JJ; D'Sa, S; Dimopoulos, MA; Garcia-Sanz, R; Hou, J; Kapoor, P; Kastritis, E; Kersten, MJ; LeBlond, V; Leiba, M; Matous, JV; Paludo, J; Qiu, L; San-Miguel, J; Tam, CS; Tedeschi, A; Thomas, SK; Tohidi-Esfahani, I; Treon, SP; Trotman, J; Varettoni, M; Vos, JM | 1 |
| Abeykoon, JP; Anderson, KC; Ansell, SM; Branagan, AR; Buske, C; Castillo, JJ; Dimopoulos, MA; Garcia-Sanz, R; Kapoor, P; Kersten, MJ; Kimby, E; Li, Y; Morel, P; Munshi, NC; Palomba, ML; Qiu, L; Roccaro, AM; Roos-Weil, D; San-Miguel, J; Sarosiek, S; Shadman, M; Stephens, D; Tam, CS; Treon, SP; Vos, J; Yi, S | 1 |
| Abeykoon, JP; Kapoor, P; Paludo, J | 1 |
| Adam, Z; Boichuk, I; Král, Z; Krejčí, M; Pour, L; Sandecká, V; Štork, M; Zeman, D | 1 |
| Ancona, G; Chiamenti, M; Codecà, C; Cona, A; d'Arminio Monforte, A; Ferrari, D; Marchetti, G; Marti, A; Merlini, E; Tesoro, D; Tincati, C | 1 |
| Minzenmayer, AN; Miranda, RN; Parekh, PK; Powell, PR | 1 |
| Baseggio, L; Dumas, C | 1 |
| Burningham, Z; Chien, HC; Halwani, AS; Li, CY; Morreall, D; Passey, DG; Patil, V; Rasmussen, KM; Sauer, BC; Yong, CM | 1 |
| Castillo, JJ; Sarosiek, S; Treon, SP | 1 |
| Eulitt, P; Fabian, D; Hemminger, J; Kelly, C; William, BM | 1 |
| Izumi, H; Komatsu, N; Nakamura, N; Noguchi, M; Ohta, Y; Sawada, T; Sekiguchi, Y; Sugimoto, K; Takizawa, H; Tomita, S; Wakabayashi, M | 1 |
| Abeykoon, JP; Ailawadhi, S; Ansell, SM; Buadi, FK; Dingli, D; Dispenzieri, A; Gertz, MA; Go, RS; Gonsalves, WI; Habermann, TM; Hayman, S; Kapoor, P; King, RL; Koehler, AB; Kourelis, T; Kumar, S; Kyle, RA; Lacy, MQ; Leung, N; Lin, Y; Paludo, J; Rajkumar, SV; Reeder, CB; Shreders, A; Warsame, R; Witzig, TE | 1 |
| Bareau, B; Baugier de Materre, A; Bene, MC; Chaoui, D; Dartigeas, C; Dupuis, J; Eveillard, JR; Herbaux, C; Laribi, K; Le Calloch, R; Leblond, V; Merabet, F; Poulain, S; Roos-Weil, D; Roussel, X; Tricot, S; Willems, L | 1 |
| Bourne, H; Sayer, JA; Willows, J; Wood, K | 1 |
| Adam, Z; Krejčí, M; Pour, L; Ševčíková, E | 1 |
| Advani, RH; Anderson, KC; Barlogie, B; Dimopoulos, MA; García-Sanz, R; Gertz, MA; Ghobrial, IM; Gregory, SA; Kastritis, E; Kimby, E; Kyle, RA; Kyriakou, C; Landgren, O; Leblond, V; Leleu, X; Maloney, D; Merlini, G; Morel, P; Morra, E; Munshi, N; Owen, RG; Rummel, M; Terpos, E; Thomas, SK; Treon, SP | 1 |
| Baratè, C; Belsito Petrizi, V; Benevolo, G; Ferrero, S; Franceschetti, S; Frustaci, AM; Gaidano, G; Gentile, M; Ghione, P; Gini, G; Goldaniga, MC; Margiotta Casaluci, G; Morra, E; Motta, M; Orsucci, L; Picardi, P; Ravelli, E; Tedeschi, A; Urbano, MA; Varettoni, M; Visco, C; Vitolo, U; Zaja, F | 1 |
| Arbasino, C; Arcaini, L; Bonfichi, M; Cazzola, M; Da Vià, M; Delmonte, M; Gotti, M; Marchioni, E; Picchiecchio, A; Sciarra, R; Varettoni, M | 1 |
| Treon, SP | 1 |
| Adam, Z; Král, Z; Krejčí, M; Mayer, J; Pour, L; Pourová, E; Ševčíková, E; Ševčíková, S | 1 |
| Dimopoulos, MA; Kastritis, E | 1 |
| Ailawadhi, S; Ansell, SM; Bergsagel, PL; Braggio, E; Buadi, FK; Chanan-Khan, A; Colgan, JP; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Go, RS; Gonsalves, WI; Greipp, PT; Grogan, M; Habermann, TM; Hayman, SR; Hwa, YL; Inwards, DJ; Jevremovic, D; Johnston, PB; Kapoor, P; Ketterling, RP; King, RL; Kumar, SK; Kyle, RA; Lacy, MQ; Leung, N; Lin, Y; Lust, JA; Markovic, SN; Mauermann, M; Micallef, IN; Mikhael, JR; Morice, WG; Novak, A; Nowakowski, GS; Porrata, LF; Rajkumar, SV; Reeder, CB; Roy, V; Russell, SJ; Sher, T; Stewart, AK; Thompson, CA; Witzig, TE; Zeldenrust, SR | 1 |
| Augustson, B; Brown, R; Gibson, J; Grigoriadis, G; Harrison, S; Ho, JP; Horvath, N; Jaksic, W; Johnston, A; Joshua, D; Kalff, A; Kalro, A; Lee, C; Mollee, P; Prince, HM; Quach, H; Roberts, AW; Spencer, A; Szer, J; Talaulikar, D; Tam, CS; Trotman, J; Ward, C; Zannettino, A | 1 |
| Hanzis, C; Ioakimidis, L; Manning, RJ; Patterson, CJ; Sheehy, P; Treon, SP; Tripsas, C | 1 |
| Jhaveri, KD; Krish, P | 1 |
| Dreyling, M; Gafter-Gvili, A; Gurion, R; Raanani, P; Shpilberg, O; Vidal, L | 1 |
| Miwa, A | 1 |
12 review(s) available for bendamustine hydrochloride and Waldenstrom Macroglobulinemia
| Article | Year |
|---|---|
Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Immunotherapy, Adoptive; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Prednisone; Receptors, Chimeric Antigen; Risk Assessment; Rituximab; Stem Cell Transplantation; Vincristine; Waldenstrom Macroglobulinemia | 2021 |
Diagnosis and management of Waldenström macroglobulinaemia-A British Society for Haematology guideline.
Topics: Bendamustine Hydrochloride; Bortezomib; Hematology; Humans; Rituximab; Waldenstrom Macroglobulinemia | 2022 |
SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia.
Topics: Bendamustine Hydrochloride; Humans; Mutation; Myeloid Differentiation Factor 88; Protein Kinase Inhibitors; Rituximab; Waldenstrom Macroglobulinemia | 2022 |
Frontline Management of Waldenström Macroglobulinemia with Chemoimmunotherapy.
Topics: Bendamustine Hydrochloride; Clinical Trials, Phase III as Topic; Cyclophosphamide; Doxorubicin; Humans; Myeloid Differentiation Factor 88; Prednisone; Randomized Controlled Trials as Topic; Retrospective Studies; Rituximab; Vincristine; Waldenstrom Macroglobulinemia | 2023 |
Waldenström's macroglobulinemia - clinical symptoms and review of therapy yesterday, today and tomorrow.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bendamustine Hydrochloride; Cyclophosphamide; Humans; Proteasome Inhibitors; Rituximab; Waldenstrom Macroglobulinemia | 2023 |
How to Sequence Therapies in Waldenström Macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Benzamides; Humans; Mutation; Myeloid Differentiation Factor 88; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Rituximab; Waldenstrom Macroglobulinemia | 2021 |
[Therapy of Waldenström´s macroglobulinaemia in the year 2014].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Humans; Immunologic Factors; Immunosuppressive Agents; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Rituximab; Vidarabine; Vincristine; Waldenstrom Macroglobulinemia | 2014 |
Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Consensus Development Conferences as Topic; Disease Progression; Everolimus; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Nitrogen Mustard Compounds; Pyrazines; Rituximab; Salvage Therapy; Sirolimus; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2014 |
[Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience].
Topics: Adenine; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Immunoglobulin M; Lenalidomide; Lymphatic Diseases; Neoplasm Recurrence, Local; Piperidines; Prednisone; Prognosis; Pyrazoles; Pyrimidines; Remission Induction; Rituximab; Splenomegaly; Thalidomide; Thrombocytopenia; Vincristine; Waldenstrom Macroglobulinemia | 2016 |
Current therapy guidelines for Waldenstrom's macroglobulinaemia.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Clinical Trials as Topic; Cyclophosphamide; Dexamethasone; Humans; Immunotherapy; Mutation; Myeloid Differentiation Factor 88; Piperidines; Practice Guidelines as Topic; Pyrazoles; Pyrimidines; Receptors, CXCR4; Rituximab; Waldenstrom Macroglobulinemia | 2016 |
Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Cyclophosphamide; Dexamethasone; Everolimus; Humans; Myeloid Differentiation Factor 88; Piperidines; Plasma Exchange; Pyrazoles; Pyrimidines; Retreatment; Risk Assessment; Rituximab; Waldenstrom Macroglobulinemia | 2017 |
Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Nitrogen Mustard Compounds; Prednisone; Recurrence; Vincristine; Waldenstrom Macroglobulinemia | 2012 |
1 trial(s) available for bendamustine hydrochloride and Waldenstrom Macroglobulinemia
| Article | Year |
|---|---|
Report of consensus panel 1 from the 11
Topics: Bendamustine Hydrochloride; Consensus; Humans; Immunoglobulin Light-chain Amyloidosis; Prospective Studies; Rituximab; Waldenstrom Macroglobulinemia | 2023 |
23 other study(ies) available for bendamustine hydrochloride and Waldenstrom Macroglobulinemia
| Article | Year |
|---|---|
Case Report: High Doses of Intravenous Immunoglobulins as a Successful Treatment for Late Onset Immune Agranulocytosis After Rituximab Plus Bendamustine.
Topics: Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dose-Response Relationship, Drug; Humans; Immunoglobulins, Intravenous; Male; Rituximab; Treatment Outcome; Waldenstrom Macroglobulinemia | 2021 |
Successful treatment with tirabrutinib for relapsed Bing-Neel syndrome following high-dose methotrexate and craniospinal irradiation.
Topics: Bendamustine Hydrochloride; Craniospinal Irradiation; Cyclophosphamide; Doxorubicin; Humans; Imidazoles; Immunoglobulin M; Male; Methotrexate; Middle Aged; Myoclonus; Prednisolone; Procarbazine; Pyrimidines; Rituximab; Vincristine; Waldenstrom Macroglobulinemia | 2022 |
A Canadian Perspective on the Treatment of Waldenström Macroglobulinemia.
Topics: Agammaglobulinaemia Tyrosine Kinase; Bendamustine Hydrochloride; Canada; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin M; Proteasome Inhibitors; Purines; Quality of Life; Rituximab; Transplantation, Autologous; Waldenstrom Macroglobulinemia | 2022 |
Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management.
Topics: Antibodies, Monoclonal; Bendamustine Hydrochloride; Humans; Immunoglobulin M; Myeloid Differentiation Factor 88; Paraproteins; Risk Assessment; Rituximab; Waldenstrom Macroglobulinemia | 2023 |
Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials.
Topics: Bendamustine Hydrochloride; Consensus; Cyclophosphamide; Humans; Rituximab; Waldenstrom Macroglobulinemia | 2023 |
Disseminated cytomegalovirus disease after bendamustine: a case report and analysis of circulating B- and T-cell subsets.
Topics: Aged; Antineoplastic Agents, Alkylating; Antiviral Agents; B-Lymphocytes; Bendamustine Hydrochloride; CD8-Positive T-Lymphocytes; Cytomegalovirus Infections; Cytomegalovirus Retinitis; Humans; Male; T-Lymphocyte Subsets; Valganciclovir; Waldenstrom Macroglobulinemia | 2019 |
An unusual case of cutaneous Waldenström macroglobulinemia with the MYD88 L265P mutation.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bone Marrow; Cell Differentiation; Diagnosis, Differential; Female; Humans; Immunoglobulin kappa-Chains; Immunoglobulin M; Lymphocytes; Lymphoma, B-Cell, Marginal Zone; Mutation; Myeloid Differentiation Factor 88; Plasma Cells; Rituximab; Skin Diseases; Treatment Outcome; Waldenstrom Macroglobulinemia | 2020 |
Crystal-storing histiocytosis in Bing-Neel syndrome.
Topics: Aged; Bendamustine Hydrochloride; Bone Marrow; Histiocytes; Histiocytosis; Humans; Immunoglobulins; Inclusion Bodies; Leukoencephalopathies; Lymph Nodes; Male; Plasma Cells; Syndrome; Waldenstrom Macroglobulinemia | 2021 |
Real-world treatment patterns and outcomes in a national study of veterans with Waldenström macroglobulinemia, 2006-2019.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Chlorambucil; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Kaplan-Meier Estimate; Piperidines; Prednisone; Progression-Free Survival; Proportional Hazards Models; Retrospective Studies; Rituximab; Treatment Outcome; Veterans; Vidarabine; Vincristine; Waldenstrom Macroglobulinemia | 2021 |
Waldenström's macroglobulinemia masquerading as ovarian cancer with peritoneal carcinomatosis, ascites, and elevated CA-125.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Bendamustine Hydrochloride; CA-125 Antigen; Female; Humans; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Rituximab; Waldenstrom Macroglobulinemia | 2019 |
A case of Waldenstrom Macroglobulinemia in which intermittent one-day administration cycles of bendamustine were effective for alleviation of nausea and maintenance of remission.
Topics: Aged; Bendamustine Hydrochloride; Humans; Male; Nausea; Remission Induction; Waldenstrom Macroglobulinemia | 2017 |
Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers; Cyclophosphamide; Dexamethasone; Drug Resistance; Female; Humans; Male; Middle Aged; Mutation; Myeloid Differentiation Factor 88; Recurrence; Rituximab; Survival Analysis; Treatment Outcome; Waldenstrom Macroglobulinemia | 2018 |
Waldenström macroglobulinemia: 2019 update on diagnosis, risk stratification, and management.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Humans; Prognosis; Risk Assessment; Rituximab; Stem Cell Transplantation; Therapeutics; Waldenstrom Macroglobulinemia | 2019 |
Bendamustine plus rituximab in newly-diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Rituximab; Waldenstrom Macroglobulinemia | 2019 |
Acquired C1-inhibitor deficiency presenting with nephrotic syndrome.
Topics: Aged; Angioedemas, Hereditary; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Humans; Male; Nephrotic Syndrome; Quality of Life; Return to Work; Rituximab; Treatment Outcome; Waldenstrom Macroglobulinemia | 2019 |
Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Follow-Up Studies; Humans; Male; Middle Aged; Recurrence; Retreatment; Retrospective Studies; Rituximab; Salvage Therapy; Treatment Outcome; Waldenstrom Macroglobulinemia | 2015 |
Successful treatment with Rituximab and Bendamustine in a patient with newly diagnosed Waldenström's Macroglobulinemia complicated by Bing-Neel syndrome.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Bone Marrow; Central Nervous System Neoplasms; Humans; Immunologic Factors; Male; Middle Aged; Nitrogen Mustard Compounds; Remission Induction; Rituximab; Treatment Outcome; Waldenstrom Macroglobulinemia | 2015 |
How I treat Waldenström macroglobulinemia.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cladribine; Cyclophosphamide; Everolimus; Gene Expression; Genetic Predisposition to Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin M; Male; Middle Aged; Molecular Targeted Therapy; Myeloid Differentiation Factor 88; Nitrogen Mustard Compounds; Oligopeptides; Piperidines; Plasmapheresis; Pyrazines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Rituximab; Sirolimus; Transplantation, Autologous; Vidarabine; Waldenstrom Macroglobulinemia | 2015 |
Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
Topics: Adenine; Advisory Committees; Antineoplastic Agents; Australia; Bendamustine Hydrochloride; Bone Marrow; Bortezomib; Humans; Immunoglobulin M; Mutation; Myeloid Differentiation Factor 88; Piperidines; Plasma Cells; Practice Guidelines as Topic; Pyrazoles; Pyrimidines; Rituximab; Societies, Medical; Waldenstrom Macroglobulinemia | 2017 |
Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management.
Topics: Age Factors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Humans; Immunoglobulin M; Rituximab; Stem Cell Transplantation; Waldenstrom Macroglobulinemia | 2017 |
Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Male; Middle Aged; Nitrogen Mustard Compounds; Recurrence; Rituximab; Treatment Outcome; Waldenstrom Macroglobulinemia | 2011 |
The Case ∣ Hyperbicarbonatemia in a patient with Waldenstrom's macroglobulinemia. Pseudohyperbicarbonatemia due to paraproteinemia.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Bicarbonates; Biomarkers; Female; Humans; Immunoglobulin M; Middle Aged; Nitrogen Mustard Compounds; Predictive Value of Tests; Rituximab; Treatment Outcome; Up-Regulation; Waldenstrom Macroglobulinemia | 2012 |
[Diagnosis and treatment of Waldenström macroglobulinemia].
Topics: Alkylating Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Diagnosis, Differential; Humans; Nitrogen Mustard Compounds; Purine Nucleosides; Rituximab; Waldenstrom Macroglobulinemia | 2012 |